Title:Application of Poloxamers for the Development of Drug Delivery System to Treat Leishmaniasis: A Review
VOLUME: 22 ISSUE: 3
Author(s):Audrey Silva, Amanda Costa, Sona Jain, Eduardo Coelho, Ricardo Fujiwara, Ricardo Scher, Rogéria Nunes and Silvio Dolabella*
Affiliation:Departamento de Farmacia, Universidade Federal de Sergipe, Sao Cristovao, 49100-000, Sergipe, Departamento de Farmacia, Universidade Federal de Sergipe, Sao Cristovao, 49100-000, Sergipe, Programa de Pos-Graduacao em Biotecnologia Industrial, Universidade Tiradentes, Aracaju, 49032-490, Sergipe, Faculdade de Medicina, Universidade Federal de Minas Gerais, Belo Horizonte, 30130-100, Minas Gerais, Departamento de Parasitologia, Universidade Federal de Minas Gerais, Belo Horizonte, 31270-901, Minas Gerais, Departamento de Morfologia, Universidade Federal de Sergipe, Sao Cristovao, 49100-000, Sergipe, Departamento de Farmacia, Universidade Federal de Sergipe, Sao Cristovao, 49100-000, Sergipe, Departamento de Farmacia, Universidade Federal de Sergipe, Sao Cristovao, 49100-000, Sergipe
Keywords:Pluronic, triblock copolymers, nanotechnology, leishmania, treatment, chemotherapy.
Abstract:Leishmaniasis is a neglected tropical disease affecting more than 1.5 million people annually,
with an annual mortality of over 20.000. The drugs used for its treatment are toxic, expensive,
require extended treatment times and present variable efficacy. The disease severity and therapy
limitations suggest the need for new antileishmanial agents. In this context, in order to identify
new options for treatment, a number of studies based on nanotechnological strategies have been carried
out. Poloxamers are triblock copolymers very often utilized for nanotherapeutic solutions, resulting
in products with better solubility, higher stability, superior therapeutic efficacy and less
toxicity. This review will discuss the physicochemical properties of the copolymers, as well as describe
the use of poloxamers for the development of therapeutic formulations to treat leishmaniasis.
